A
Absorption. The process by which a drug moves from its site of administration into the bloodstream. For peptides, absorption is a major challenge due to enzymatic degradation and poor membrane permeability.
ADME. Abbreviation for Absorption, Distribution, Metabolism, and Excretion -- the four processes that determine a drug's pharmacokinetic profile and how the body handles a compound over time.
Agonist. A substance that binds to a receptor and activates it, producing a biological response. A full agonist produces the maximum possible response; a partial agonist produces a submaximal response even at full receptor occupancy. For example, semaglutide is a GLP-1 receptor agonist.
Allosteric modulator. A substance that binds to a receptor at a site different from the primary (orthosteric) binding site, enhancing or reducing the receptor's response to its natural ligand without directly activating or blocking it.
Amino acid. The building blocks of peptides and proteins. There are 20 standard amino acids encoded by human DNA, each with a unique side chain (R group) that determines its chemical properties. Non-standard and unnatural amino acids also exist and are used in peptide modification strategies.
Angiogenesis. The formation of new blood vessels from existing vasculature. Essential for wound healing and tissue repair, but also involved in tumor growth, as cancers require new blood supply to grow beyond a small size.
Antagonist. A substance that binds to a receptor without activating it, blocking the receptor and preventing activation by agonists. A competitive antagonist competes with the agonist for the same binding site; a non-competitive antagonist binds elsewhere and reduces the maximum response.
Antibody. A large Y-shaped protein produced by the immune system to identify and neutralize foreign substances. Anti-drug antibodies can develop against therapeutic peptides, potentially reducing their efficacy or causing allergic reactions.
AUC (Area Under the Curve). The total drug exposure over time, calculated as the area under the plasma concentration-time curve. A key pharmacokinetic parameter used to assess bioavailability and compare formulations.
B
BDNF (Brain-Derived Neurotrophic Factor). A protein that supports neuron survival, growth, differentiation, and synaptic plasticity. Several peptides, including Semax and Selank, are studied for their ability to increase BDNF expression in the brain.
Bioavailability. The fraction of an administered dose that reaches systemic circulation in active form. Intravenous administration has 100% bioavailability by definition. Most peptides have very low oral bioavailability (often less than 1%) due to enzymatic degradation in the gastrointestinal tract and poor absorption across the intestinal epithelium.
Bioequivalence. Two formulations of a drug are bioequivalent if they produce the same rate and extent of absorption (same AUC and Cmax within predefined limits, typically 80-125%).
BLA (Biologics License Application). The regulatory submission to the FDA for approval of a biological product (including larger peptides and proteins produced by recombinant DNA technology). Analogous to an NDA for small molecules.
Blinding. A study design feature where participants, investigators, or both are unaware of treatment assignments. Single-blind: participants do not know; double-blind: neither participants nor investigators know; triple-blind: participants, investigators, and data analysts are all blinded.
C
Case-control study. An observational study that identifies individuals with a disease or outcome (cases) and individuals without (controls), then compares past exposures between the two groups. Useful for studying rare diseases but susceptible to recall and selection bias.
Cathelicidin. A family of antimicrobial peptides found in mammals. LL-37 is the only human cathelicidin, produced primarily by neutrophils and epithelial cells. It has broad-spectrum antimicrobial activity and immunomodulatory effects.
Clearance (CL). The volume of plasma from which a drug is completely removed per unit time. Determines, along with volume of distribution, the drug's half-life. Peptides are cleared through enzymatic degradation and renal filtration.
Cmax. The maximum (peak) plasma concentration of a drug after administration. Along with Tmax (time to reach Cmax), it characterizes the absorption profile of a drug.
Cohort study. An observational study that follows a group of individuals over time to compare outcomes between those exposed and not exposed to a factor. Prospective cohorts follow participants forward; retrospective cohorts use historical data.
Confidence interval (CI). A range of values within which the true population parameter is expected to fall with a specified probability (usually 95%). Wider intervals indicate less precision. If a 95% CI for a treatment difference includes zero, the result is not statistically significant at the 0.05 level.
Confounding variable. A variable that is associated with both the exposure and the outcome, potentially creating a false appearance of a direct relationship between them. Randomization is the most effective method for controlling confounders.
Crossover study. A study design in which each participant receives all treatments being compared, in a random sequence separated by washout periods. Each participant serves as their own control, increasing statistical power.
Cyclization. The process of connecting the ends of a linear peptide to form a ring structure. Cyclization can be head-to-tail (N-terminus to C-terminus), side chain-to-side chain, or via other linkages. It increases protease resistance, reduces conformational flexibility, and can improve receptor binding affinity and membrane permeability.
Cytokine. A broad category of small signaling proteins released by cells to regulate immunity, inflammation, and hematopoiesis. Includes interleukins, interferons, tumor necrosis factors, and chemokines. Some peptides modulate cytokine production.
D
D-amino acid. The mirror-image (enantiomeric) form of the standard L-amino acids found in human proteins. D-amino acids are not recognized by most natural proteases, so substituting them into a peptide at key positions increases resistance to enzymatic degradation.
DAC (Drug Affinity Complex). A chemical modification that allows a peptide to bind reversibly to serum albumin in the bloodstream, dramatically extending the peptide's circulating half-life by piggybacking on albumin's approximately 19-day half-life.
Dose-response curve. A graph showing the relationship between drug dose and the magnitude of effect. Key features include the EC50 (dose producing 50% of maximum effect), maximum efficacy (ceiling effect), and the therapeutic window.
Double-blind. A study design in which neither the participants nor the investigators know which treatment each participant receives, minimizing bias in both the experience of participants and the assessment of outcomes.
DPP-IV (Dipeptidyl Peptidase-4). A serine protease enzyme that cleaves dipeptides from the N-terminus of proteins containing a proline or alanine in the second position. Rapidly degrades native GLP-1 and GIP (half-life reduced to 1-2 minutes). GLP-1 receptor agonists like semaglutide are modified to resist DPP-IV cleavage.
E
EC50 (Half-maximal Effective Concentration). The concentration of a drug that produces 50% of its maximum possible effect. A lower EC50 indicates a more potent drug. Used primarily in in vitro and preclinical pharmacology.
Efficacy. The ability of a drug to produce the desired therapeutic effect. In pharmacology, efficacy refers to the maximum effect achievable; in clinical trials, it refers to performance under controlled (ideal) conditions, as opposed to effectiveness (performance in real-world conditions).
Endpoint. A specific, predefined outcome measure used to evaluate the effect of a treatment in a clinical trial. Primary endpoints are the main outcomes the study is powered to detect; secondary endpoints are additional measures of interest.
Endogenous. Produced naturally within the body. Endogenous peptides include hormones like insulin, GLP-1, and oxytocin. Opposite of exogenous (administered from outside the body).
Endotoxin. A component of the outer membrane of gram-negative bacteria (lipopolysaccharide/LPS) that can cause fever, inflammation, and potentially fatal septic shock if injected into the bloodstream. Endotoxin testing (LAL assay) is critical for injectable peptide products.
EUA (Emergency Use Authorization). An FDA mechanism that allows the use of unapproved medical products during a public health emergency when no adequate alternatives exist. Used prominently during the COVID-19 pandemic.
Exogenous. Originating from outside the body. An exogenous peptide is one that is administered rather than produced naturally.
F
First-pass metabolism. The metabolism of a drug by the liver (and to some extent the gut wall) before it reaches systemic circulation. When a drug is taken orally, it absorbs from the intestine into the portal vein and passes through the liver, where enzymes may inactivate a substantial portion. This is a major reason for the low oral bioavailability of most peptides.
Forest plot. A graphical display used in meta-analyses showing the results of individual studies and the combined (pooled) estimate. Each study appears as a square (point estimate) with horizontal lines (confidence intervals), and the overall pooled result appears as a diamond.
Funnel plot. A scatter plot used to detect publication bias in meta-analyses. Studies are plotted by their effect size and precision (usually standard error). Asymmetry in the funnel shape suggests that small studies with negative results are missing from the literature.
G
GIP (Glucose-dependent Insulinotropic Polypeptide). An incretin hormone released by K-cells in the duodenum and jejunum after eating. Stimulates insulin secretion and has effects on fat metabolism. GIP is the co-target (alongside GLP-1) of tirzepatide.
GLP-1 (Glucagon-Like Peptide-1). An incretin hormone released by intestinal L-cells after eating. Stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite. Native GLP-1 has a half-life of only 1-2 minutes due to DPP-IV degradation, driving the development of long-acting analogs like semaglutide.
GMP (Good Manufacturing Practice). A system of regulations and guidelines ensuring that pharmaceutical products are consistently produced and controlled according to quality standards. GMP covers all aspects of production, from raw materials and facility design to staff training and quality testing.
GHS-R (Growth Hormone Secretagogue Receptor). Also known as the ghrelin receptor (GHSR1a). A G protein-coupled receptor that, when activated, stimulates growth hormone release from the pituitary and increases appetite. The target for GH-releasing peptides like ipamorelin and GHRP-6.
GHRH (Growth Hormone-Releasing Hormone). A 44-amino acid hypothalamic peptide that stimulates growth hormone synthesis and release from anterior pituitary somatotroph cells. Synthetic analogs include sermorelin, tesamorelin, and CJC-1295.
H
Half-life (t1/2). The time required for the plasma concentration of a substance to decrease by 50%. Determines dosing frequency. Native GLP-1 has a half-life of approximately 2 minutes; semaglutide, through pharmaceutical modifications, has a half-life of approximately 7 days.
Hazard ratio (HR). A measure of effect in survival/time-to-event analyses. An HR of 1.0 means no difference between groups; HR less than 1.0 means lower risk in the treatment group; HR greater than 1.0 means higher risk. For example, HR = 0.75 means the treatment group has 25% lower rate of the event at any given time.
Heterogeneity. In meta-analysis, the degree of variability in study results beyond what would be expected from sampling error alone. Measured by the I-squared statistic: 0% indicates no heterogeneity, 25% low, 50% moderate, 75% high. High heterogeneity may indicate that the studies are measuring different things and should not be pooled.
HPLC (High-Performance Liquid Chromatography). An analytical technique used to separate, identify, and quantify components of a mixture. The standard method for assessing peptide purity, producing a chromatogram where each peak represents a different component.
I
IC50 (Half-maximal Inhibitory Concentration). The concentration of an inhibitor required to reduce a biological process by 50%. Lower IC50 values indicate more potent inhibitors.
IGF-1 (Insulin-like Growth Factor 1). A 70-amino acid hormone produced primarily by the liver in response to growth hormone signaling. Mediates many of GH's anabolic effects, including muscle growth, bone formation, and cell proliferation.
Immunogenicity. The ability of a substance to provoke an immune response. For therapeutic peptides, immunogenicity can lead to the formation of anti-drug antibodies (ADAs) that may neutralize the drug's effect, alter its pharmacokinetics, or cause allergic reactions.
In silico. Studies performed using computer simulations or computational models. Includes molecular docking studies, pharmacokinetic modeling, and machine learning-based drug design.
In vitro. "In glass." Studies conducted outside a living organism, in cell cultures, tissue preparations, or biochemical assays. Valuable for understanding mechanisms but least predictive of clinical outcomes.
In vivo. "In life." Studies conducted in living organisms. Includes both animal studies and human clinical trials. Animal in vivo studies are more predictive than in vitro, but approximately 90% of compounds that succeed in animal studies fail in human trials.
Incretin. A gut hormone that enhances glucose-dependent insulin secretion after eating. The two main incretins are GLP-1 (from L-cells) and GIP (from K-cells). The incretin effect accounts for 50-70% of the insulin response to oral glucose.
IND (Investigational New Drug). An application submitted to the FDA before a new drug can be tested in human clinical trials. The IND includes preclinical safety data, manufacturing information, and the proposed clinical trial protocol. If the FDA does not object within 30 days, trials may proceed.
Intention-to-treat (ITT). An analysis strategy in which all participants are analyzed according to their original randomized group assignment, regardless of adherence, protocol deviations, or dropout. Preserves the benefits of randomization and provides a real-world estimate of effectiveness.
Inverse agonist. A substance that binds to a receptor and produces an effect opposite to that of an agonist. Different from an antagonist, which merely blocks the receptor without producing an effect.
L
Ligand. Any molecule that binds to a specific receptor. Includes agonists, antagonists, inverse agonists, and allosteric modulators. Natural ligands for peptide receptors include hormones, neurotransmitters, and growth factors.
Lipidation. The attachment of a lipid (fatty acid) chain to a peptide, enabling it to bind reversibly to serum albumin and thereby extend its circulating half-life. The key strategy behind the long half-lives of semaglutide (C18 fatty diacid) and tirzepatide (C20 fatty diacid).
Lyophilization. Freeze-drying; a process that removes water from a frozen product by sublimation. Produces a dry, stable powder that can be stored longer than liquid formulations. Most research peptides and some pharmaceutical peptides are supplied in lyophilized form and must be reconstituted before use.
M
Melanocortin receptor. A family of five G protein-coupled receptors (MC1R through MC5R) involved in diverse physiological processes. MC1R: skin pigmentation. MC2R: adrenal cortisol production. MC3R and MC4R: energy homeostasis and appetite. MC4R is also involved in sexual function (target of bremelanotide). MC5R: exocrine gland secretion.
Meta-analysis. A statistical technique that combines quantitative results from multiple independent studies to produce a single pooled estimate with greater precision and statistical power than any individual study. The quality of a meta-analysis depends critically on the quality and homogeneity of the included studies.
Molecular weight (MW). The mass of a molecule, measured in Daltons (Da) or kilodaltons (kDa). Small molecule drugs are typically less than 500 Da; peptides range from approximately 500 to 5,000 Da; proteins are larger. Molecular weight affects renal clearance, membrane permeability, and formulation options.
N
NDA (New Drug Application). The regulatory submission to the FDA requesting approval to market a new drug for human use. Includes all preclinical, clinical, manufacturing, and labeling data. Standard review takes 10-12 months; priority review takes 6 months.
NEP (Neutral Endopeptidase/Neprilysin). A zinc-dependent metalloprotease that cleaves various peptides including natriuretic peptides, enkephalins, substance P, and bradykinin. A major enzyme responsible for the degradation of many therapeutic peptides in the bloodstream.
NNH (Number Needed to Harm). The number of patients who need to be treated before one additional patient experiences a specific adverse event compared to control. Higher NNH values indicate a safer treatment.
NNT (Number Needed to Treat). The number of patients who need to be treated for one additional patient to benefit compared to control. Calculated as 1 divided by the absolute risk reduction. Lower NNT values indicate more effective treatments.
Non-inferiority trial. A clinical trial designed to demonstrate that a new treatment is not worse than a standard treatment by more than a predefined margin. Used when the new treatment may offer advantages in convenience, cost, or side effects even if not superior in efficacy.
O
Off-label use. The use of a drug for an indication, dosage, route, or patient population not specified in its approved labeling. Legal for physicians to prescribe but the manufacturer cannot promote. Estimated to account for 20-30% of all prescriptions.
Open-label. A study design in which both participants and investigators know which treatment is being administered. Susceptible to placebo effects and observer bias, especially for subjective outcomes.
P
PEGylation. The covalent attachment of polyethylene glycol (PEG) polymer chains to a peptide or protein. Increases the molecule's hydrodynamic size (reducing renal clearance), shields it from proteolytic degradation, and reduces immunogenicity. Trade-off: may reduce receptor binding affinity.
Peptide bond. The covalent chemical bond formed between the carboxyl group (-COOH) of one amino acid and the amino group (-NH2) of another through a condensation reaction that releases water. The bond has partial double-bond character due to resonance, constraining the backbone geometry.
Per-protocol analysis. An analysis that includes only participants who completed the study as specified in the protocol. May overestimate treatment effects by excluding dropouts, but estimates efficacy under ideal conditions.
Pharmacodynamics (PD). The study of what a drug does to the body -- its mechanism of action, biological effects, and the relationship between drug concentration and effect magnitude.
Pharmacokinetics (PK). The study of what the body does to a drug -- how it is absorbed, distributed, metabolized, and eliminated over time. Key PK parameters include bioavailability, Cmax, Tmax, AUC, half-life, clearance, and volume of distribution.
Placebo. An inactive treatment (e.g., saline injection, sugar pill) used as a control in clinical trials. The placebo effect is the improvement observed in the placebo group, which can be substantial for subjective outcomes like pain, mood, and energy.
Post-hoc analysis. A statistical analysis conducted after a study is completed that was not pre-specified in the study protocol. Post-hoc findings are hypothesis-generating only and should not be considered confirmatory evidence.
Power (statistical). The probability that a study will detect a true effect when one exists. Conventionally set at 80% or 90%. An underpowered study may fail to detect a real effect (false negative/Type II error).
Prodrug. A pharmacologically inactive compound that is metabolized in the body into an active drug. Some peptide formulations use prodrug strategies to improve stability or absorption.
Publication bias. The tendency for studies with positive or significant results to be published more frequently than those with negative or null results. Creates a distorted literature that overestimates treatment effects.
P-value. The probability of observing results at least as extreme as those obtained, assuming the null hypothesis (no effect) is true. A p-value of 0.05 means a 5% probability of observing such results if the treatment truly has no effect. Does not measure effect size, clinical importance, or the probability that the hypothesis is true.
R
RCT (Randomized Controlled Trial). A clinical study in which participants are randomly assigned to treatment or control groups. Randomization balances known and unknown confounders between groups, providing the strongest evidence for causal relationships between treatments and outcomes. Considered the gold standard for evaluating therapeutic efficacy.
Receptor. A protein molecule, usually on the cell surface or inside the cell, that binds to a specific ligand and triggers a cellular response. Cell surface receptors include G protein-coupled receptors (GPCRs), receptor tyrosine kinases, and ion channels. Intracellular receptors include nuclear hormone receptors.
Reconstitution. The process of dissolving a lyophilized (freeze-dried) peptide in a suitable solvent (typically bacteriostatic water or sterile water) to prepare it for injection. Proper reconstitution technique is important to maintain peptide integrity.
Regression to the mean. The statistical tendency for extreme measurements to move closer to the average on subsequent measurements, regardless of any intervention. This phenomenon can create the false impression that a treatment is working when improvement would have occurred naturally.
Relative risk (RR). The ratio of the event rate in the treatment group to the event rate in the control group. RR = 1.0 means no difference; RR less than 1.0 means the treatment reduces risk; RR greater than 1.0 means the treatment increases risk.
S
Secretagogue. A substance that promotes the secretion of another substance. Growth hormone secretagogues (GHS) stimulate GH release from the anterior pituitary. Examples include ghrelin mimetics (GHRP-6, GHRP-2, ipamorelin) and non-peptide GHS (MK-677/ibutamoren).
Signal transduction. The process by which a signal from outside a cell (e.g., a peptide binding to its receptor) is transmitted through a series of molecular events inside the cell to produce a specific response. Major signaling cascades include cAMP/PKA, IP3/DAG, JAK/STAT, and MAPK/ERK pathways.
Solid-phase peptide synthesis (SPPS). The standard method for manufacturing synthetic peptides. Amino acids are added one at a time to a growing peptide chain anchored to an insoluble resin bead. Each addition involves a deprotection step and a coupling step. After completion, the peptide is cleaved from the resin and purified. Developed by Bruce Merrifield (Nobel Prize, 1984).
Specificity. The ability of a drug to bind to its intended target without affecting other targets. Peptides generally have higher target specificity than small molecule drugs due to their larger size and more precise molecular interactions.
Stapled peptide. A peptide in which a hydrocarbon bridge has been introduced across one or two turns of an alpha-helix, locking the peptide into its bioactive conformation. Stapling improves stability, protease resistance, cell permeability, and potency.
Subcutaneous (SC). Under the skin. The most common injection route for peptide therapeutics. The peptide is deposited in the fatty tissue between the skin and the muscle, from which it gradually absorbs into the bloodstream.
Surrogate endpoint. A laboratory measurement or physical sign used as a substitute for a clinically meaningful endpoint. For example, HbA1c is a surrogate endpoint for diabetes complications. Drugs may receive accelerated approval based on surrogate endpoints, with post-marketing studies required to confirm clinical benefit.
Systematic review. A comprehensive, structured review of all available evidence on a specific research question, using a predefined search strategy and explicit inclusion/exclusion criteria. May or may not include a meta-analysis (quantitative pooling of results).
T
Telomerase. An enzyme (a reverse transcriptase) that adds TTAGGG DNA repeats to telomeres, the protective caps at the ends of chromosomes. Telomere shortening is associated with cellular aging and senescence. Epithalon is studied for its purported ability to activate telomerase, though evidence is limited and primarily from a single research group.
Therapeutic index (TI). The ratio of the dose that produces toxicity to the dose that produces the desired therapeutic effect. A wide therapeutic index means a large margin of safety; a narrow therapeutic index means small dose changes can lead to toxicity or loss of efficacy.
Tmax. The time after drug administration at which the maximum plasma concentration (Cmax) is achieved. Reflects the rate of drug absorption.
Type I error (false positive). Concluding that a treatment has an effect when it actually does not. The significance level (alpha, typically 0.05) is the acceptable probability of a Type I error.
Type II error (false negative). Concluding that a treatment has no effect when it actually does. The probability of a Type II error is beta; statistical power (1 - beta) is the probability of correctly detecting a true effect.
V
Vd (Volume of Distribution). A theoretical volume that relates the total amount of drug in the body to the plasma concentration. A large Vd indicates extensive distribution into tissues; a small Vd indicates the drug remains mostly in the bloodstream. Affects half-life and dosing calculations.
VEGF (Vascular Endothelial Growth Factor). A signaling protein that stimulates the formation of new blood vessels (angiogenesis). Several tissue repair peptides, including BPC-157 and TB-500, upregulate VEGF expression, which may contribute to their wound-healing effects but also raises theoretical concerns about tumor vascularization.
W
WADA (World Anti-Doping Agency). The international body that publishes and maintains the Prohibited List of substances and methods banned in competitive sports. Many peptides are WADA-prohibited, including growth hormone secretagogues, GH-releasing peptides, and various other peptide hormones. The list is updated annually.
Washout period. In a crossover study, the time between treatment periods during which the previous treatment is eliminated from the body. Must be long enough (typically 5 or more half-lives) to avoid carryover effects from the first treatment into the second period.
X
Xenobiotic. Any chemical substance found within an organism that is not naturally produced by or expected to be present in that organism. Exogenous peptides administered for therapeutic or research purposes are xenobiotics. The body's xenobiotic metabolism pathways (primarily hepatic cytochrome P450 enzymes) are less relevant for peptide drugs, which are primarily degraded by proteases rather than metabolic enzymes.